CML Publications December 2025
As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications from low- and middle-income countries.
Clinical CML papers
How can we chop CML with an ASXL1?
Cortes J. Blood, December 2025
open access publication
(Commentary on the article highlighted in September 2025: Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Shanmuganathan N. et al Blood 2025)
Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial
Cortes JE et al. Blood, December 2025
Is there a best frontline therapy in chronic myeloid leukemia?
Jain AG et al. Haematologica, December 2025 (epub ahead of print)
open access publication
Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centred perspective
Ernst P et al. Leukemia, December 2025 (epub ahead of print)
open access publication
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-a2b in newly diagnosed chronic phase chronic myeloid leukemia
Yeung DT et al. Br J Haematol, December 2025 (epub ahead of print)
How I treat advanced phases of CML?
Mauro MJ. Blood, December 2025 (epub ahead of print)
Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission
Flynn KE & Atallah E. Haematologica, December 2025 (epub ahead of print)
open access publication
Prognostic factors in chronic myeloid leukemia at diagnosis and for treatment-free remission
Rea D. Haematologica, December 2025 (epub ahead of print)
open access publication
Treatment of chronic myeloid leukemia chronic phase in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
Vandenberghe P et al. Hematology, December 2025
open access publication
Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia
Toptas T et al. Hematology, December 2025
open access publication
Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia
Cheng F & Li W et al. Haematologica, December 2025 (epub ahead of print)
open access publication
Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia
Suzuki K et al. Int J Hematol, December 2025 (epub ahead of print)
Empirical and projected economic burden of chronic myeloid leukemia in Sweden from 2015 – 2030: A population-based study
Chen EY et al. Br J Haematol, December 2025 (epub ahead of print)
open access publication
Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real-world cohort
Schweneker K et al. Int J Hematol, December 2025 (epub ahead of print)
open access publication
Scientific CML papers
Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients
Cayssials E et al. Cancer Immunol Immunother, December 2025
open access publication
Stroma-driven horizontal transfer of TCA-related proteins mediates metabolic plasticity and imatinib resistance in chronic myeloid leukemia
Chroscicki P et al. Cell Commun Signal, December 2025 (epub ahead of print)
open access publication
Immune surveillance in chronic myeloid leukemia: Tumor antigen expression and CD8(+) T cell function in the context pf treatment-free remission
Kvásnik P et al. Arch Immunol Therp Exp (Warsz), December 2025
open access publication
Targeting Musashi-2 to counteract senescence and resistance in chronic myeloid leukemia: enhancing the efficacy of imatinib therapy
Arif K et al. BMC Cancer, December 2025 (epub ahead of print)
open access publication
An overview of strategies and challenges adopted to silence BCR::ABL gene by small interfering RNA
Fancello L et al. Nanomedicine (Lond), December 2025
P38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia
Bhat M et al. Exp Cell Res, December 2025 (epub ahead of print)
Pediatric CML Papers
Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG(Plus)-CML 2023
Fan Z et al. Cancer, December 2025 – open access publication
LMIC CML Papers
Insights into treatment-free remission (TFR) outcomes in chronic myeloid leukemia (CML) – a tertiary centre experience in Malaysia
Liam CCK et al. Blood Res, December 2025
open access publication
Clinical outcomes of patients with chronic myeloid leukemia with asciminib provided by a compassionate program in Brazil
Pagnano K. et al. Blood Global Hematology December 2025
The needs of the many outweigh the needs of the few
Lipton JH., Blood Global Hematology December 2025
(Commentary on the article: Clinical outcomes of patients with chronic myeloid leukemia with asciminib provided by a compassionate program in Brazil. Pagnano K. et al. Blood Global Hematology December 2025)